Literature DB >> 20556505

An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer.

Sahar M A Mahmoud1, Emma C Paish, Desmond G Powe, R Douglas Macmillan, Andrew H S Lee, Ian O Ellis, Andrew R Green.   

Abstract

Studies in mice have shown that thymic-derived CD4+ CD25+ regulatory T cells (T reg; FOXP3(+) lymphocytes) inhibit an antitumour immune response. Additional studies have also reported that the T reg population increases in peripheral blood and tumour tissues from patients with cancer. However, the relationship between the T reg population and the patient prognosis remains controversial. Our aim was to determine the prognostic value of T reg cell density in breast cancer using immunohistochemical assessment of FOXP3, which has been shown to be the optimal marker for T regs. Tissue microarrays were used, and the density of FOXP3(+) cells was determined in a series of 1445 cases of well-characterised primary invasive breast carcinoma cases with long-term follow up. FOXP3(+) cell numbers were counted in tumour nests, in tumour-adjacent stroma, and in distant stroma. The total number of FOXP3(+) cells significantly correlated with higher tumour grade (r (s) = 0.37, P < 0.001) and ER negativity (Mann-Whitney U test, P < 0.001). In addition, FOXP3 infiltration positively correlated with HER2 expression and basal phenotype subclass. On univariate analysis, FOXP3(+) cells were associated with a worse prognosis (P = 0.012, log rank = 6.36). This association was found for intratumoural FOXP3(+) and for tumour-adjacent stromal FOXP3(+)-cells (tumour-cell associated FOXP3, P = 0.001 and log rank 10.35). However, the number of FOXP3(+) cells was not found to be an independent prognostic factor in multivariate analysis. We therefore conclude that FOXP3(+) infiltrating cells do not have a dominant role in breast cancer prognosis and suggest that other inflammatory cell subsets may be more critical variables.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556505     DOI: 10.1007/s10549-010-0987-8

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  62 in total

1.  Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India.

Authors:  Parveen Jahan; V R Vinish Ramachander; G Maruthi; S Nalini; K Prasanna Latha; T S R Murthy
Journal:  Tumour Biol       Date:  2013-12-13

2.  Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

Authors:  Soizic Garaud; Laurence Buisseret; Cinzia Solinas; Chunyan Gu-Trantien; Alexandre de Wind; Gert Van den Eynden; Celine Naveaux; Jean-Nicolas Lodewyckx; Anaïs Boisson; Hughes Duvillier; Ligia Craciun; Lieveke Ameye; Isabelle Veys; Marianne Paesmans; Denis Larsimont; Martine Piccart-Gebhart; Karen Willard-Gallo
Journal:  JCI Insight       Date:  2019-08-13

3.  Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients.

Authors:  Neta S Zuckerman; Hongxiang Yu; Diana L Simons; Nupur Bhattacharya; Valeria Carcamo-Cavazos; Ning Yan; Frederick M Dirbas; Denise L Johnson; Erich J Schwartz; Peter P Lee
Journal:  Int J Cancer       Date:  2012-11-26       Impact factor: 7.396

Review 4.  Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.

Authors:  Caroline Jochems; Jeffrey Schlom
Journal:  Exp Biol Med (Maywood)       Date:  2011-04-12

Review 5.  The dual role of the X-linked FoxP3 gene in human cancers.

Authors:  Margaret Redpath; Bin Xu; Leon C van Kempen; Alan Spatz
Journal:  Mol Oncol       Date:  2011-03-30       Impact factor: 6.603

6.  Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma.

Authors:  Hulya Sahin Ozkan; Mustafa Umit Ugurlu; Perran Fulden Yumuk; Handan Kaya
Journal:  Pathol Oncol Res       Date:  2020-07-17       Impact factor: 3.201

7.  Development of novel murine mammary imaging windows to examine wound healing effects on leukocyte trafficking in mammary tumors with intravital imaging.

Authors:  Tammy Sobolik; Ying-Jun Su; Will Ashby; David K Schaffer; Sam Wells; John P Wikswo; Andries Zijlstra; Ann Richmond
Journal:  Intravital       Date:  2016-01-13

Review 8.  The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers.

Authors:  Qingli Jiao; Aiguo Wu; Guoli Shao; Haoyu Peng; Mengchuan Wang; Shufeng Ji; Peng Liu; Jian Zhang
Journal:  J Thorac Dis       Date:  2014-09       Impact factor: 2.895

9.  Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer.

Authors:  Chunling Ma; Qunyuan Zhang; Jian Ye; Fang Wang; Yanping Zhang; Eric Wevers; Theresa Schwartz; Pamela Hunborg; Mark A Varvares; Daniel F Hoft; Eddy C Hsueh; Guangyong Peng
Journal:  J Immunol       Date:  2012-10-03       Impact factor: 5.422

10.  Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry.

Authors:  Anna Marie Mulligan; Irene Raitman; Linda Feeley; Dushanthi Pinnaduwage; Linh T Nguyen; Frances P O'Malley; Pamela S Ohashi; Irene L Andrulis
Journal:  Clin Cancer Res       Date:  2012-12-04       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.